Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-Dose vs. Standard-Dose Influenza Vaccines in Lung Transplant Recipients
NCT07192458Phase 2Recruiting
- Sponsor
- Vanderbilt University Medical Center
- Start
- Sep 2025
- Primary completion
- Dec 2028
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of influenza virus vaccine, split virion in influenza (2 arms), sponsored by Vanderbilt University Medical Center. Primary endpoints: Geometric Mean Titers of Influenza Vaccine Antibodies, Number of participants reporting solicited injection site reactions and 1 more. Started Sep 2025; status: recruiting.
02
Drugs
influenza virus vaccine, split virion
03
Conditions
influenza
Beyond the preview
Go deeper on NCT07192458.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07192458.